Plunkett Research Online: Immuron Ltd

IMMURON LTD (IMRN:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a.....



Immuron Ltd
Ticker: IMRN
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 61 398245254
Fax: 61 398227735
Address: Chapman Street
Unit 10, 25-37
Blackburn North
Melbourne, VIC 3130 Australia

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Contacts Description
Steven LydeamoreCEO
Phillip HainsCFO/Secretary
See More
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a.....See More See More

Auditor: Grant Thornton Audit Pty Ltd
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202220212020201920182017
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
NameTitleSalary (AUD)Bonus (AUD)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: